🚨 Just out in Annals of Oncology! 🌊 Dive into the latest on liquid biopsy for colorectal cancer🩸: What’s the best approach to monitor ctDNA? Tumor-informed vs. tumor-agnostic strategies for minimal residual disease detection. 📄Read here: [annalsofoncology.org/article/S0923-…]

🧠My thoughts after this review by Belén Martínez Castedo Daniel González Camblor on ctDNA analysis: * Tumor-informed assays = higher sensitivity but need tumor tissue. * Tumor-agnostic = broader use, lower sensitivity. 💡Multi-omics integration is key.

Minimal residual disease in colorectal cancer: Tumor-informed vs tumor-agnostic approaches 📊 🔍 Key Insights: ✅ctDNA enhances risk stratification & adjuvant therapy guidance. ✅Tumor-informed strategies show higher sensitivity. 🎯 ✅Tumor-agnostic methods offer broader

La biopsia líquida revoluciona el manejo del cáncer, ofreciendo diagnóstico temprano, monitoreo en tiempo real y tratamientos personalizados. #BiopsiaLíquida #Oncología No te pierdas la noticia ⬇️ @CIBERONC Noelia Tarazona biopsia-liquida.ciberonc.es/liquid-biopsy-…

🔥 So proud of Jorge Martin Arana Belén Martínez Castedo Daniel González Camblor presenting their work at the X Liquid Biopsy Symposium🩸Their research on ctDNA and epigenomics in pancreatic and CRC showcases their talent and dedication. 👏Congratulations on pushing science forward! #SantiagoLiquidBiopsy

Este TEAM lo ha hecho posible❤️👇, a la guía de mi mentor Andrés Cervantes y al apoyo de becas SEOM Grupo Español de Tratamiento de Tumores Digestivos Instituto de Salud Carlos III (ISCIII)

💥Proud of our team for presenting cutting-edge work on ctDNA🩸and tumor-immune profiling in CRC at #EACR2025! 🔬From resistance mechanisms to new immunotherapy strategies - science made in Valencia INCLIVA 🇪🇸✨ 🔝Belén Martínez Castedo Daniel González Camblor Blanca García Micó

🔥 We got the cover of the June issue of Nature Cancer with our paper! 🌟 A huge honor and a recognition of the team’s hard work. 🔗 lnkd.in/dd6dE7A4 📄 See lnkd.in/dfd3hfi2